Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $199,975.88 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88. Following the completion of the transaction, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $102,857.14.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.34, for a total transaction of $158,712.82.

Entrada Therapeutics Trading Down 8.1%

Entrada Therapeutics stock traded down $0.62 during trading on Wednesday, hitting $7.00. The company had a trading volume of 229,319 shares, compared to its average volume of 334,500. The stock has a market cap of $272.58 million, a price-to-earnings ratio of -1.77 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1-year low of $5.02 and a 1-year high of $16.45. The company’s 50 day simple moving average is $7.08 and its 200-day simple moving average is $9.36.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. As a group, analysts forecast that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TRDA shares. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, Roth Capital reiterated a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Institutional Trading of Entrada Therapeutics

Large investors have recently made changes to their positions in the company. Odyssean LLC acquired a new stake in Entrada Therapeutics in the second quarter valued at approximately $230,000. Nantahala Capital Management LLC acquired a new position in Entrada Therapeutics during the 2nd quarter worth approximately $2,212,232,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $276,000. Bank of America Corp DE purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $426,000. Finally, 5AM Venture Management LLC acquired a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at $29,854,949,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.